Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Entrectinib (RXDX-101) is an inhibitor of TrkA (IC50: 1.7 nM), TrkB (IC50: 0.1 nM), and TrkC (IC50: 0.1 nM), as well as anaplastic lymphoma kinase (ALK; IC50: 1.6 nM) and C-ros oncogene 1 (ROS1; IC50: 0.2 nM). Entrectinib blocks proliferation of ALK-dependent cell lines, including those with C1156Y or L1196M resistance mutations, and inhibits ALK‐dependent signaling. It has been shown to inhibit the growth of a non-small cell lung Y cell line bearing an EML4-ALK rearrangement. In mice bearing various ROS1, Trk, or ALK-driven xenografts, Entrectinib has been shown to induce tumor regression.
説明 | Entrectinib (RXDX-101) is an inhibitor of TrkA (IC50: 1.7 nM), TrkB (IC50: 0.1 nM), and TrkC (IC50: 0.1 nM), as well as anaplastic lymphoma kinase (ALK; IC50: 1.6 nM) and C-ros oncogene 1 (ROS1; IC50: 0.2 nM). Entrectinib blocks proliferation of ALK-dependent cell lines, including those with C1156Y or L1196M resistance mutations, and inhibits ALK‐dependent signaling. It has been shown to inhibit the growth of a non-small cell lung Y cell line bearing an EML4-ALK rearrangement. In mice bearing various ROS1, Trk, or ALK-driven xenografts, Entrectinib has been shown to induce tumor regression. |
ターゲット&IC50 | TrkA:1.7 nM, TrkB:0.1 nM, TrkC:0.1 nM, ALK:1.6 nM |
In vitro | Entrectinib effectively inhibits ALK‐dependent signaling and specificity blocks proliferation of ALK-dependent cell lines. Entrectinib also significantly inhibits cell growth of the NCI‐H2228 cell line bearing the EML4-ALK rearrangement. |
In vivo | In mice bearing Karpas-299 and SR-786 xenografts, Entrectinib (p.o.) induces complete tumor regression. In NPM-ALK transgenic mice, Entrectinib induces complete regression of tumor masses observed in the thymus and in lymph nodes. [2] In the NB xenograft model, Entrectinib cotreatment enhanced the efficacy of conventional chemotherapy. [3] |
細胞研究 | NLF, NLF-TrkB, SY5Y or SY5Y-TrkB cells are plated in 96 well plates, and they are exposed to drug at different concentrations (1, 5, 10, 20, 30, 50 and 100 nM of entrectinib, 1.5 μM Irino and 50 μM TMZ, respectively) for one hr followed by addition of 100 ng/mL of BDNF. Plates are harvested at 24, 48, and 72 hr following addition of drug. The plates are processed and cell viability is analyzed using a standard SRB assay protocol[2]. |
別名 | RXDX-101, NMS-E628 |
分子量 | 560.64 |
分子式 | C31H34F2N6O2 |
CAS No. | 1108743-60-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 67 mg/mL(119.5 mM)
DMSO: 50 mg/mL (89.18 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
5% DMSO+95% Saline: 5 mg/mL (8.92 mM, suspension)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Entrectinib 1108743-60-7 Angiogenesis Autophagy Immunology/Inflammation Tyrosine Kinase/Adaptors ROS Trk receptor ROS Kinase ALK ALK tyrosine kinase receptor Inhibitor Cluster of differentiation 246 RXDX-101 Anaplastic lymphoma kinase (ALK) RXDX 101 RXDX101 Trk Receptor inhibit NMS-E628 Tropomyosin related kinase receptor Anaplastic lymphoma kinase CD246 NMS-E-628 NMS-E 628 inhibitor